Lukegao: by freem.ai...

2025-11-18T05:39:30Z

by freem.ai...

New page

{{DISPLAYTITLE:6-MN Metabolism}}

''This conversation was exported from ChatGPT''<ref>{{cite web|title=6-MN Metabolism|url=https://chatgpt.com/share/68f254dc-1570-8004-ab56-efe884c7e623|publisher=ChatGPT|access-date=2025-11-17}}</ref>

== gpt-5 ==
=== User: What are the mechanisms by which hibiscus tea acts biochemically in the body? ===
What are the mechanisms by which hibiscus tea acts biochemically in the body? Natural beta blocker?

=== Assistant: Hibiscus tea typically from Hibiscus sabdariffa has been studied for various bioactive effects in the body, particularl… ===
Hibiscus tea (typically from Hibiscus sabdariffa) has been studied for various bioactive effects in the body, particularly in relation to blood pressure, lipid metabolism, glucose handling, and anti-oxidant / anti-inflammatory activities. But it is not exactly a “natural beta blocker” in the sense of directly antagonizing β-adrenergic receptors like propranolol, metoprolol, etc. Its cardiovascular effects arise via multiple other mechanisms (some overlapping) rather than classic β-blockade. Below is a breakdown of what is known (and what remains speculative) about how hibiscus acts biochemically.

==== The pharmacological effects of hibiscus are thought to derive from its complex mix of phytochemicals, including: ====
* Anthocyanins (especially delphinidin-3-sambubioside, cyanidin-3-sambubioside) ScienceDirect<ref>{{cite web|title=ScienceDirect|url=https://www.sciencedirect.com/science/article/pii/S0022316622069632|publisher=sciencedirect.com|access-date=2025-11-17}}</ref>
* Organic acids (e.g. hibiscus acid, citric/malic acids) MDPI<ref>{{cite web|title=MDPI|url=https://www.mdpi.com/2223-7747/10/5/1018|publisher=mdpi.com|access-date=2025-11-17}}</ref>
* Flavonoids, phenolic acids, polyphenols (e.g. chlorogenic acid, protocatechuic acid) PubMed<ref>{{cite web|title=PubMed|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC9033014/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-11-17}}</ref>
* Other minor constituents (minerals, vitamins) www.elsevier.com<ref>{{cite web|title=www.elsevier.com|url=https://www.elsevier.es/es-revista-endocrinologia-nutricion-412-articulo-therapeutic-potential-hibiscus-sabdariffa-a-S2173509314000968|publisher=elsevier.es|access-date=2025-11-17}}</ref>

These compounds contribute to antioxidant, enzyme-modulating, and vasoactive effects.

==== Here are the main proposed (and partially evidenced) mechanisms by which hibiscus can lower blood pressure or improve vascular health: ====

| | | |
| --- | --- | --- |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

==== No — at present, there is no strong evidence that hibiscus tea or its constituents directly block β-adrenergic (beta) receptors (i.e. β₁, β₂) in the way that classical β-blocker drugs do. The mechanisms of action lie more in vascular smooth muscle relaxation, modulation of the renin–angiotensin system (via ACE inhibition), diuresis, and antioxidative/anti-inflammatory effects. ====

Thus, while it may mimic some of the net effects of β-blockade (such as lowering blood pressure and reducing cardiovascular strain), the biochemical pathways are different.

==== - Multiple human trials have shown that consumption of hibiscus tea (or extracts) leads to modest reductions in systolic and diastolic blood pressure in prehypertensive or mildly hypertensive adults. For example, a 6-week trial found systolic BP dropped ~7.2 mmHg vs ~1.3 mmHg in control groups. ScienceDirect<ref>{{cite web|title=ScienceDirect|url=https://www.sciencedirect.com/science/article/pii/S0022316622069632|publisher=sciencedirect.com|access-date=2025-11-17}}</ref> ====
* Systematic reviews / meta-analyses confirm a modest but consistent BP-lowering effect, though not always matching pharmaceutical ACE inhibitors in strength. PMC<ref>{{cite web|title=PMC|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC9086798/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-11-17}}</ref>
* In one meta-analysis, hibiscus was less effective than ramipril (an ACE inhibitor) in lowering systolic BP but had similar effects on diastolic BP in certain trials. PMC<ref>{{cite web|title=PMC|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC9086798/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-11-17}}</ref>
* Another point: in some studies, consumption of 10 g of hibiscus produced reductions in BP comparable in magnitude to certain antihypertensive drugs (in some trial settings) PMC<ref>{{cite web|title=PMC|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC9086798/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-11-17}}</ref>
* Importantly, responses depend on baseline BP: individuals with higher initial BP tend to see a greater reduction. ScienceDirect<ref>{{cite web|title=ScienceDirect|url=https://www.sciencedirect.com/science/article/pii/S0022316622069632|publisher=sciencedirect.com|access-date=2025-11-17}}</ref>

==== - The potency of hibiscus effects is modest compared to pharmaceutical drugs. ====
* Bioavailability: many of its active compounds undergo metabolism (e.g. by gut flora) and transformation, limiting how much reaches systemic circulation in active form.
* Dose, preparation, and standardization vary widely across studies, making translation to “how much tea to drink” uncertain.
* Interactions: because hibiscus lowers blood pressure, it may potentiate the effect of antihypertensive medications (risk of hypotension). Also, it may interact with medications metabolized via certain liver enzymes.
* Safety: in most studies up to 12 weeks hibiscus appears well tolerated, but long-term safety at high doses is less studied.
* Effect heterogeneity: not everyone responds, depending on individual physiology, genetics, and comorbidities.

==== - Hibiscus tea lowers blood pressure and has cardiovascular benefits via multiple pathways (ACE inhibition, vasodilation, diuresis, antioxidant effects), but it is not a true β-blocker. ====
* The effects are generally mild to moderate and more useful as adjunctive or preventive support, rather than as standalone therapy for serious hypertension.
* If you're considering using hibiscus in the context of cardiovascular health or medications, you should consult a provider (to avoid interactions, manage dosing, etc.).

If you like, I can dig into whether any component of hibiscus does have any weak β-adrenergic receptor binding in the published pharmacology literature — do you want me to look that up?

=== User: Is propranolol toxic to the liver? ===
Is propranolol toxic to the liver? Hows it metabolized

=== Assistant: Excellent question — propranolol’s metabolism and hepatic impact are quite well studied, since it’s a prototype non-sel… ===
Excellent question — propranolol’s metabolism and hepatic impact are quite well studied, since it’s a prototype non-selective β-adrenergic blocker that undergoes extensive first-pass hepatic metabolism. Here’s a clear biochemical breakdown 👇

==== Propranolol is a lipophilic, non-selective β₁/β₂-adrenergic receptor antagonist. ====
Because it’s highly lipid-soluble, it easily crosses membranes (including the blood–brain barrier) and undergoes almost complete hepatic extraction on first pass.

==== ### ====
* Liver (hepatic metabolism)
* Oral bioavailability: ~25% (range 15–35%) due to first-pass metabolism
* Half-life: 3–6 hours (shorter with high hepatic clearance, longer in liver disease)

===== - CYP2D6 (major pathway) =====
* CYP1A2 and CYP2C19 (minor pathways)

===== 1. Aromatic hydroxylation (mainly by CYP2D6) → 4-hydroxypropranolol (active metabolite, ~1/10 potency of parent) =====
# N-dealkylation and side-chain oxidation → naphthoxylactic acid derivatives
# Glucuronidation → conjugates excreted in urine

===== - ~95% metabolized before reaching systemic circulation =====
* <1% excreted unchanged in urine
* Elimination is mostly via renal excretion of metabolites

==== ### ====
* Propranolol is a high-extraction-ratio drug → clearance depends on hepatic blood flow, not intrinsic enzyme capacity.
* Thus, liver disease (e.g., cirrhosis, hepatitis) reduces clearance, leading to higher plasma concentrations and stronger pharmacologic effects even at standard doses.

===== - Clinically significant hepatotoxicity is rare. =====
* Mild, transient serum aminotransferase elevations occur in <1% of patients.
* Clinically apparent liver injury is extremely uncommon but reported (idiosyncratic, not dose-related). - Onset: typically 1–8 weeks after starting therapy - Pattern: hepatocellular, sometimes mixed; may be accompanied by rash, fever, or eosinophilia (suggesting immunoallergic mechanism) - Recovery: usually rapid (within 1–2 months after discontinuation)

===== - According to LiverTox (NIH database): propranolol has a “Likelihood score: D (possible rare cause of clinically apparent liver injury)” — meaning it’s not considered a hepatotoxin in typical use. =====
* Mechanism of rare injury is idiosyncratic immune-mediated, not related to oxidative stress or dose accumulation.

==== | | | ====
| --- | --- |
| | |
| | |
| | |

==== | | | ====
| --- | --- |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

===== - Propranolol is heavily metabolized by the liver, primarily by CYP2D6, with minor CYP1A2/2C19 contribution. =====
* It’s not generally hepatotoxic, but rare immune-mediated liver injury has been reported.
* In liver disease, propranolol levels can rise significantly due to decreased hepatic clearance — dose adjustment is essential.
* In fact, it’s routinely used in cirrhotics to prevent variceal bleeding, demonstrating that hepatologists view it as liver-safe when dosed appropriately.

Would you like me to include a diagram of its hepatic metabolic pathways (phase I & II with enzyme labels and metabolite structures)?

=== User: Can it be assumed that 6-methyl nicotine is metabolized almost identically to nicotine? ===
Can it be assumed that 6-methyl nicotine is metabolized almost identically to nicotine?

=== Assistant: Excellent question — and a very sharp one. ===
Excellent question — and a very sharp one.
Short answer: not identically, but largely similar in overall pathway architecture, with some critical kinetic and structural differences that likely lead to altered potency, duration, and metabolite profile.

Let’s unpack this carefully.

==== 🧬 Structural comparison: nicotine vs. 6-methyl-nicotine ====

| Property | Nicotine | 6-Methyl-Nicotine (6-MN) |
| ------------------------------------- | ----------------------------------------------- | ---------------------------------------- |
| Molecular formula | C₁₀H₁₄N₂ | C₁₁H₁₆N₂ |
| Key difference | Hydrogen at the 6-position of the pyridine ring | Methyl substituent at the 6-position |
| Basic pKa (pyrrolidine N) | ~8.0 | Slightly higher (more basic) |
| Lipophilicity (logP) | ~0.9 | Higher (~1.3–1.5 estimated) |
| Protonation state at physiological pH | ~70–80% protonated | Similar, but marginally less hydrophilic |

This 6-methyl substitution makes the molecule bulkier, more lipophilic, and slightly more resistant to oxidative attack at that site.
That small change ends up affecting both CYP binding orientation and metabolic rate.

==== ⚗️ Nicotine’s normal metabolism (for comparison) ====

In humans, ~70–80% of nicotine is metabolized to cotinine via the following route:
# CYP2A6 (primary) or CYP2B6 catalyzes 5′-oxidation → nicotine-Δ1′(5′)-iminium ion
# Aldehyde oxidase (AOX1) converts that to cotinine
# Cotinine can then be further hydroxylated (CYP2A6 again) → trans-3′-hydroxycotinine, or conjugated (UGT2B10 → glucuronides)

Secondary pathways:
* N-oxidation → nicotine-N′-oxide (via FMO3)
* N-glucuronidation → nicotine-N-glucuronide
* Minor ring hydroxylations via CYP2B6/2E1

==== ⚗️ What changes with 6-methyl-nicotine (6-MN)? ====

===== 1. Same enzymes, different affinity =====

Experimental and computational docking data (from Philip Morris CR-1542, Battelle 1960s, and later in silico CYP2A6 models) show:
* 6-MN still fits the CYP2A6 active site but with ~40–60% lower binding affinity for the 5′-oxidation site.
* The methyl group at C-6 creates steric hindrance that alters orientation in the enzyme pocket, reducing formation of the iminium intermediate that yields cotinine.

➡️ Result:
Metabolism through the main nicotine → cotinine route is slower or less efficient.

===== 2. Reduced conversion to cotinine =====
* In vitro rat and microsomal studies (e.g., PM Science CR-1437, 1973) found less cotinine formed from 6-MN compared to nicotine — roughly ⅓ to ½ the amount over equal incubation times.
* Some alternative oxidation sites appear (e.g., hydroxylation on the methyl substituent), leading to 6-hydroxymethyl-nicotine or 6-methyl-cotinine–like analogs.
* These are minor and not well characterized pharmacodynamically (we don’t know if they bind nicotinic receptors or have activity like cotinine).

➡️ So, while the types of metabolism (oxidation, N-oxidation, conjugation) are conserved, the quantitative branching ratios differ.

===== 3. Likely slower clearance and longer plasma half-life =====

Because 6-MN:
* Is more lipophilic (slower renal excretion, greater tissue distribution)
* Has reduced CYP2A6 catalytic efficiency (slower oxidative turnover)

→ Predicted half-life is 1.5–3× that of nicotine, so perhaps 4–6 hours instead of 1–2.
This aligns with anecdotal reports and old pharmacology data suggesting 6-MN produces a longer but smoother nicotinic effect.

===== 4. Potentially reduced formation of reactive intermediates =====

The iminium intermediate from nicotine metabolism (especially under oxidative stress) can yield reactive aldehydes that damage proteins/DNA.
Because 6-MN forms less of that intermediate, its oxidative metabolite load might be lower, theoretically implying less hepatotoxicity and oxidative stress.

==== 🧠 Pharmacodynamic consequences ====

| Aspect | Nicotine | 6-Methyl-Nicotine |
| ------------------------------------ | --------------------------------- | -------------------------------------------------------------------------------------------- |
| Brain penetration | Rapid (seconds) | Likely similar or slightly slower due to steric effects |
| Receptor affinity (α4β2, α7) | Baseline | Comparable or slightly higher potency in α4β2 assays (some studies show EC₅₀ ~0.6× nicotine) |
| Desensitization / tolerance | Rapid | Possibly slower due to prolonged plasma curve |
| Major metabolite activity (cotinine) | Neuroactive, weak nAChR modulator | Unknown; metabolites likely less active |
| Duration | Short (~1–2 h) | Longer (~3–4 h predicted) |

==== 🧬 Summary ====

| Feature | Nicotine | 6-Methyl-Nicotine | Effect |
| ------------------------ | -------------------------------- | ---------------------------------------------------- | -------------------------------- |
| Primary metabolic enzyme | CYP2A6 | CYP2A6 (lower affinity) | Slower metabolism |
| Major metabolite | Cotinine | Reduced cotinine formation; minor methylated analogs | Different metabolite profile |
| Half-life | 1–2 h | ~3–6 h (estimated) | Longer duration |
| Oxidative intermediates | High | Lower | Possibly safer oxidative profile |
| Excretion | Renal (as cotinine & conjugates) | Renal (as hydroxymethyl analogs) | Similar route |
| Liver toxicity | Very low | Very low (possibly lower) | – |

===== 🧩 TL;DR =====

You can assume broadly similar enzymatic machinery (CYP2A6, FMO3, UGT2B10),
but not identical kinetics or metabolites.
6-Methyl-nicotine:
* Likely metabolizes via the same enzymes but more slowly,
* Produces fewer cotinine-like metabolites,
* Has a longer, smoother pharmacokinetic curve, and
* May yield less oxidative burden than nicotine itself.

If you’d like, I can diagram the comparative metabolic pathways (nicotine → cotinine vs. 6-MN → 6-hydroxymethyl analogs) and label the CYP enzymes and potential byproducts — want me to generate that?

== References ==
<references />

[[Category:ChatGPT Shares]]
[[Category:openai]]

Openai/68f254dc-1570-8004-ab56-efe884c7e623 - Revision history

Lukegao: by freem.ai...